Highlights of the important and the interesting from the world of healthcare:
Another lackluster biotech IPO: Although shares of Trius Therapeutics closed flat on the anti-infective drug developer’s first day of trading, no matter what happened the company’s public debut has to be considered a disappointment. After hoping for a price of $12 to $14 a share, the company slashed its price to $5. The dramatic price decline shows once again, that investors have little interest in biotechs that are losing money and have no products on the market.
Big payday at Omnicare: Retiring Omnicare CEO Joe Gemunder looks to be walking away with an outrageous $133 million package. Not too shabby for an exec who led a company with an overall -12 percent return to shareholders over the last five years.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
No surprise in Missouri: Missouri voters by a nearly 3-to-1 margin passed a ballot measure that would exempt the state from the so-called individual mandate of the health reform law. The vote is perhaps a bit of a sting to the Obama administration, but ultimately a hollow gesture.
About that small government: Eighty-nine percent of Americans support legislation that would put new drug safety measures in place, and less than half say that the federal government is doing enough to ensure the safety of U.S.-made drugs. Sounds like an appetite for big government.
It’s not easy choosing a doctor: With a dearth of available information, most people spend more time and effort shopping for a tv than a doctor.
Genzyme and Sanofi: The Sanofi-Aventis and Genzyme drama continues to play out, with the two said to be deep in negotiations. The problem is that the two appear to be far apart in price, so if the deal is going to happen one side will likely need to cave.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Photo from flickr user azrainman
